NCT00464802View on ClinicalTrials.gov

Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 30, 2007

Study Completion Date

June 30, 2007

Conditions
Healthy
Interventions
DRUG

MOA-728

Trial Locations (1)

85044

Phoenix

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00464802 - Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects | Biotech Hunter | Biotech Hunter